They showed the p-value for the various stages of disease. That is all you are going to get until the multivariate numbers are released for CLIA. That was the data. There is also a new marker that has been identified that is stronger and will likely yield better multivariate numbers. All you need to know is that it is stage independent and all stages are statistically significant and no variability between stages. Also need to know they are taking on a multiple marker, or portfolio approach, so Pharma has a one stop shop for Alzheimer diagnosis. Good strategy in my opinion. Differentiates them from the competition. That is huge.